Edition:
United States

Catalyst Pharmaceuticals Inc (CPRX.OQ)

CPRX.OQ on NASDAQ Stock Exchange Capital Market

3.47USD
16 Oct 2018
Change (% chg)

-- (--)
Prev Close
$3.47
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
141,673
52-wk High
$4.51
52-wk Low
$2.20

Chart for

About

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's... (more)

Overall

Beta: 1.63
Market Cap(Mil.): $234.22
Shares Outstanding(Mil.): 84.55
Dividend: --
Yield (%): --

Financials

  CPRX.OQ Industry Sector
P/E (TTM): -- 86.20 32.69
EPS (TTM): -0.20 -- --
ROI: -42.00 0.73 14.32
ROE: -42.26 1.82 16.04

BRIEF-Catalyst Pharmaceuticals Reports Q1 GAAP Loss Per Share $0.06

* CATALYST PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 09 2018

BRIEF-Catalyst Pharmaceuticals Announces Enrollment Of First Patient In Phase 3 Trial Of Firdapse In Musk Antibody Positive Myasthenia Gravis

* CATALYST PHARMACEUTICALS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 3 TRIAL OF FIRDAPSE® IN MUSK ANTIBODY POSITIVE MYASTHENIA GRAVIS Source text for Eikon: Further company coverage:

Apr 19 2018

Competitors

Earnings vs. Estimates